QTTB:NASDAQ, Q32 Bio Inc.
QTTB stock overview
Q32 Bio Inc. (QTTB:NASDAQ) closed at $8.65 on October 23, 2026,
down 1.70% on the day.
The stock trades 63.3% below its 52-week high of $23.57
and 354.1% above its 52-week low of $1.91.
Over the past year, it gained 214.3%.
Q32 Bio Inc. is part of the Health Care sector.
Key figures
- Price
- $8.65
- Day change
- -1.70%
- Volume
- 403,793
- Average volume
- 715,778
- Market cap
- 257M+
- 52-week range
- $1.91 – $23.57
- 50-day average
- $11.26
- 200-day average
- $9.08
Price action over the past year
In 252 trading sessions since October 23, 2025, QTTB closed higher on 118 days (47%).
Its best day was July 13, 2026 (+90.72%) and its worst was May 28, 2026 (-19.77%).
The stock moved 10% or more in a single session 23 times.
It opened at least 5% above the previous day's high 4 times.
Recent signals
QTTB news
-
Oct 1, 2026:
This Biotech Had Good News for Hair Loss Sufferers. So Why Is the Stock Sinking?
-
Oct 1, 2026:
Nektar Stock Sinks Despite Promising Hair Loss Treatment Data
-
Sep 30, 2026:
Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026
-
Sep 21, 2026:
Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026
-
Sep 14, 2026:
Q32 Bio Appoints Jose Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer
-
Sep 14, 2026:
Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer
-
Sep 7, 2026:
Down 23.1% in 4 Weeks, Here's Why Q32 Bio (QTTB) Looks Ripe for a Turnaround
-
Sep 6, 2026:
These 2 ‘Monster Growth' Stocks Aren't Done Climbing, Say Analysts
About Q32 Bio Inc.
Homology Medicines Inc is a US-based genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.
Similar stocks
Find more stocks like QTTB with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.